P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE

Sylvain Choquet, Andrew Clark, Cécile Renard, Ben Uttenthal, Sridhar Chaganti, Ralf Ulrich Trappe, Patrizia Comoli, Xinyuan Duan, Baodong Xing, Charley Wu, Laurence Gamelin, Jan-Henrik Terwey, Anke Friedetzky, Daan Dierickx

Open source

DOI: 10.1097/01.hs9.0000972440.80732.55
Published: 8
Container: HemaSphere
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/01.hs9.0000972440.80732.55,
  title = {P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE},
  author = {Sylvain Choquet and Andrew Clark and Cécile Renard and Ben Uttenthal and Sridhar Chaganti and Ralf Ulrich Trappe and Patrizia Comoli and Xinyuan Duan and Baodong Xing and Charley Wu and Laurence Gamelin and Jan-Henrik Terwey and Anke Friedetzky and Daan Dierickx},
  year = {2023},
  journal = {HemaSphere},
  doi = {10.1097/01.hs9.0000972440.80732.55},
  url = {https://doi.org/10.1097/01.hs9.0000972440.80732.55}
}

RIS

TY  - JOUR
TI  - P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE
AU  - Sylvain Choquet
AU  - Andrew Clark
AU  - Cécile Renard
AU  - Ben Uttenthal
AU  - Sridhar Chaganti
AU  - Ralf Ulrich Trappe
AU  - Patrizia Comoli
AU  - Xinyuan Duan
AU  - Baodong Xing
AU  - Charley Wu
AU  - Laurence Gamelin
AU  - Jan-Henrik Terwey
AU  - Anke Friedetzky
AU  - Daan Dierickx
PY  - 2023
JO  - HemaSphere
DO  - 10.1097/01.hs9.0000972440.80732.55
UR  - https://doi.org/10.1097/01.hs9.0000972440.80732.55
ER  -

APA

Choquet, S., Clark, A., Renard, C., Uttenthal, B., Chaganti, S., Trappe, R. U., Comoli, P., Duan, X., Xing, B., Wu, C., Gamelin, L., Terwey, J., Friedetzky, A., & Dierickx, D. (2023). P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE. HemaSphere. https://doi.org/10.1097/01.hs9.0000972440.80732.55

Source records

doaj · retrieved 2026-09-27T11:13:52.352Z